AIMS: Extracellular ATP acting on the P2Y11 receptor regulates inflammatory cells. We hypothesized that polymorphisms in the receptor could influence the risk of acute myocardial infarction (AMI). METHODS AND RESULTS: In the Malmö diet and cancer AMI case-control study (n = 3732) the P2Y11 gene Thr-87 polymorphism was present in 19.8% of the controls and 22.9% in AMI patients (OR 1.21; P = 0.03). Stronger associations were found in patients with family history (FH) of AMI, 1.32; early-onset (EO) AMI, 1.43; or EO AMI combined with FH, 1.50; supporting a genetic mechanism. The Thr-87 homozygotes had an even greater risk of AMI, 1.94 (P = 0.04); and 2.48 in the EO AMI subgroup, suggesting a genetic dosage effect. In the cardiovascular risk factor group (n = 6055), 21.3% carried the Thr-87 allele. C-reactive protein was elevated in Thr-87 carriers: 1.6 mg/L vs. 1.3 mg/L (P = 0.001). No difference was seen for blood pressure, lipids, body mass index, smoking, or diabetes mellitus. CONCLUSION: The common Ala-87-Thr polymorphism of the P2Y11 receptor is associated with AMI and increased levels of C-reactive protein. We hypothesize that an inflammatory mechanism might be involved. The P2Y11 receptor is a promising new drug target in the prevention of AMI.
AIMS: Extracellular ATP acting on the P2Y11 receptor regulates inflammatory cells. We hypothesized that polymorphisms in the receptor could influence the risk of acute myocardial infarction (AMI). METHODS AND RESULTS: In the Malmö diet and cancer AMI case-control study (n = 3732) the P2Y11 gene Thr-87 polymorphism was present in 19.8% of the controls and 22.9% in AMI patients (OR 1.21; P = 0.03). Stronger associations were found in patients with family history (FH) of AMI, 1.32; early-onset (EO) AMI, 1.43; or EO AMI combined with FH, 1.50; supporting a genetic mechanism. The Thr-87 homozygotes had an even greater risk of AMI, 1.94 (P = 0.04); and 2.48 in the EO AMI subgroup, suggesting a genetic dosage effect. In the cardiovascular risk factor group (n = 6055), 21.3% carried the Thr-87 allele. C-reactive protein was elevated in Thr-87 carriers: 1.6 mg/L vs. 1.3 mg/L (P = 0.001). No difference was seen for blood pressure, lipids, body mass index, smoking, or diabetes mellitus. CONCLUSION: The common Ala-87-Thr polymorphism of the P2Y11 receptor is associated with AMI and increased levels of C-reactive protein. We hypothesize that an inflammatory mechanism might be involved. The P2Y11 receptor is a promising new drug target in the prevention of AMI.
Authors: Maria D Dănilă; Andreea Privistirescu; Oana M Duicu; Corina D Rațiu; Denis Angoulvant; Danina M Muntean; Adrian Sturza Journal: Mol Cell Biochem Date: 2017-02-17 Impact factor: 3.396
Authors: Hyojin Ko; Arijit Das; Rhonda L Carter; Ingrid P Fricks; Yixing Zhou; Andrei A Ivanov; Artem Melman; Bhalchandra V Joshi; Pavol Kovác; Jan Hajduch; Kenneth L Kirk; T Kendall Harden; Kenneth A Jacobson Journal: Bioorg Med Chem Date: 2009-05-15 Impact factor: 3.641
Authors: Maria Paz Prada; Arsalan U Syed; Olivia R Buonarati; Gopireddy R Reddy; Matthew A Nystoriak; Debapriya Ghosh; Sergi Simó; Daisuke Sato; Kent C Sasse; Sean M Ward; Luis F Santana; Yang K Xiang; Johannes W Hell; Madeline Nieves-Cintrón; Manuel F Navedo Journal: Elife Date: 2019-03-01 Impact factor: 8.140
Authors: Peter Humburg; Seiko Makino; Benjamin P Fairfax; Vivek Naranbhai; Daniel Wong; Evelyn Lau; Luke Jostins; Katharine Plant; Robert Andrews; Chris McGee; Julian C Knight Journal: Science Date: 2014-03-07 Impact factor: 47.728
Authors: Carola Ledderose; Sophie Bromberger; Christian J Slubowski; Koichiro Sueyoshi; Dilan Aytan; Yong Shen; Wolfgang G Junger Journal: Sci Signal Date: 2020-09-29 Impact factor: 8.192